시장보고서

상품코드

1515384

세계의 연부육종 시장 : 치료유형별, 투여경로별, 유통채널별, 최종사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율 예측(2024-2032년)

Soft Tissue Sarcoma Market, By Treatment Type, By Route of Administration, By Distribution Channel, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 06월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 400 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

연부육종 시장 규모는 2023년 28억 7,632만 달러로 2024년부터 2032년까지 연평균 복합 성장률(CAGR) 5.4%로 확대

연부육종 시장 - 시장 역학

연부육종을 보다 깊이 이해하기 위한 지속적인 조사가 시장 수요를 촉진

연부육종 치료 시장의 확장은 주로 세포 분열과 증식을 조절하는 특정 유전자의 비정상적인 활성에 의해 추진됩니다. 암 유전자라고 불리는 이들 유전자는 연부육종 세포 내에서 돌연변이와 활성화를 일으켜, 그 결과 억제가 없는 성장이나 급속한 증식을 일으킵니다. 또한, 연부육종 세포는 세포의 증식과 분열을 촉진하는 신호 전달 분자인 증식 인자를 대량으로 생산할 수 있습니다. 연부육종은 드문 유형의 암으로 간주되지만, 그럼에도 불구하고 생명을 위협하는 심각한 질병이며 과소 평가해서는 안됩니다. 연부육종은 다른 유형의 암에 비해 유병률이 낮음에도 불구하고 여전히 세계에서 상당수의 사람들이 앓고 있습니다. 또한 연부육종의 원인이 완전히 밝혀지지 않았다는 사실은이 질병을 더 잘 이해하고보다 효과적인 치료 전략을 개발하기위한 지속적인 연구의 필요성을 강조합니다.

연부육종 시장 - 주요 인사이트

우리의 리서치 애널리스트의 분석에 따르면 세계 시장은 예측 기간(2024-2032년)에 CAGR 약 5.4%로 연간 성장할 것으로 추정됩니다.

치료 유형별로 화학요법이 2023년 최대 시장 점유율을 나타낼 것으로 예측됩니다.

최종 사용자 세분화에서는 2023년 병원이 주요 유형이었습니다.

지역별로는 북미가 2023년 주요 수익원이었습니다.

연부육종 시장 - 세분화 분석 :

세계 연부육종 시장은 치료 유형, 투여 경로, 유통 채널, 최종 사용자 및 지역에 따라 세분화됩니다.

시장은 치료 유형별로 5가지로 분류: 표적 요법, 화학요법, 혈관신생 억제제, 방사선 요법, 기타입니다. 화학요법은 수년간의 효능과 다양한 육종 아형에 대한 광범위한 적용으로 현재 연부육종 시장의 치료 상황을 지배하고 있습니다. 표적 치료와 다른 고급 치료가 나타났음에도 불구하고 화학 요법은 신속하게 분열하는 암세포를 전신적으로 표적화하는 능력으로 인해 국소 및 전이성 질환 모두에 적합하기 때문에 여전히 요점이 있습니다. 화학 요법의 다용도는 수술 및 방사선과 같은 다른 치료법과의 병용을 가능하게 하고, 전반적인 치료 효과를 증가시킵니다. 게다가, 화학요법은 프로토콜이 확립되어 있고, 새로운 치료법에 비해 비교적 저비용이라는 것도 시장에서의 우위성에 기여하고 있습니다.

시장은 최종 사용자에 의해 네 가지 범주로 나뉩니다: 병원, 재택치료, 전문센터 및 기타. 연부육종 시장에서 병원이 주요한 최종 사용자가 되고 있는 것은 그 종합적인 자원과 복잡한 암 치료를 관리하는 능력에 의한 점이 큽니다. 병원은 집학적 치료를 제공하며 수술, 화학요법, 방사선요법, 지지요법을 조합한 치료를 필요로 하는 육종 환자에게 매우 중요합니다. 전문 종양 전문의의 존재, 고급 진단 도구, 부작용 및 합병증 관리 능력으로 병원은 초기 치료와 지속적인 치료 모두에 적합한 환경이됩니다. 게다가 병원은 임상시험이나 첨단연구의 거점이 되는 경우가 많아 환자는 최첨단의 치료나 보다 높은 수준의 치료를 받을 수 있습니다.

연부육종 시장 - 지리적 통찰

지역적으로, 이 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카의 각 지역으로 퍼져 있습니다. 이 지역은 비즈니스를 전개하는 국가에 의해 더 구분됩니다. 북미 시장은 예측 기간 동안 최대 시장 점유율을 기록하고 2023년에는 주요 수익 지위를 구축할 것으로 예측됩니다. 미국암협회에 따르면 2016년에는 추정 12,390명이 연부육종 및 관련암으로 진단되었습니다. 연부육종의 이환율의 높이, 이 질환에 대한 인식 증가, 헬스케어에 대한 주목의 높아짐, 의료 인프라의 확립 등이 시장 수익의 성장을 가속하는 주요 요인입니다.

연부육종 시장 - 경쟁 구도 :

경쟁이 심한 연부육종(STS) 시장에서는 주요 기업들이 전략적 제휴를 맺어 제품 라인업을 충실히 하고 있습니다. 다른 제약기업, 연구기관, 학술센터와 손을 잡으면 기업들은 각각의 전문지식, 자원, 기술을 결집하여 혁신을 추진하고 새로운 치료법과 진단 도구를 개발할 수 있습니다. 이러한 제휴는 데이터나 지식의 공유도 촉진하여 연구개발의 페이스를 가속시킵니다. 또한 파트너십은 기업 시장 도달범위를 확대하여 새로운 지역 및 환자 집단에 대한 액세스를 가능하게 합니다. 효율적인 치료법에 대한 수요는 일반적인 종양 발생률이 증가함에 따라 증가하고 있습니다. 그 결과 다국적 기업은 혁신적인 의약품을 창출하기 위한 연구개발에 수익의 상당 부분을 투자하고 있습니다. 고급 약물 전달 시스템과 관련된 일부 품목은 FDA 승인을 기다리고 있습니다. 담낭 종양을 치료하는 고급 의약품에 대한 수요 증가는 시장 확대를 더욱 촉진할 것으로 예상됩니다.

소개
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제12장 주요 벤더 분석 : 연부육종 업계

경쟁 대시보드
기업 프로파일
- Genentech USA
- Pfizer, Inc.
- Eli Lilly and Company
- Bristol-Myers Squibb
- Hoffmann-La Roche Ltd.
- Johnson &Johnson, Inc.
- GlaxoSmithKline
- Teva Pharmaceuticals
- Celgene Corporation
- 기타

제13장 애널리스트의 전방위 전망

JHS 24.07.26

REPORT HIGHLIGHT

Soft Tissue Sarcoma Market size was valued at USD 2,876.32 Million in 2023, expanding at a CAGR of 5.4% from 2024 to 2032.

Soft tissue sarcoma is a form of cancer originating in soft tissues like muscles, tendons, fat, lymph and blood vessels, and nerves. While they can develop in any part of the body, they are frequently located in the arms, legs, chest, and abdomen. With around 50 distinct types, identifying soft tissue sarcomas can pose a challenge. While some types predominantly affect adults, others are more common in children. The most common form of treatment is surgical removal, although radiation therapy and chemotherapy may also be recommended depending on the tumor's size, nature, location, and aggressiveness.

Soft Tissue Sarcoma Market- Market Dynamics

Need for continued research to better comprehend this disease to propel market demand

The expansion of the soft tissue sarcoma treatment market is chiefly propelled by the aberrant activity of specific genes governing cell division and growth. These genes, termed oncogenes, may undergo mutations or activation within soft tissue sarcoma cells, resulting in unchecked growth and rapid proliferation. Additionally, soft tissue sarcoma cells may produce high levels of growth factors, which are signaling molecules that promote cell growth and division. Although soft tissue sarcoma is considered a rare type of cancer, it is nonetheless a serious and life-threatening disease that should not be underestimated. Despite its lower prevalence compared to other types of cancer, soft tissue sarcoma still affects a significant number of people worldwide. Moreover, the fact that the causes of soft tissue sarcoma are not fully understood underscores the need for continued research to better comprehend this disease and develop more effective treatment strategies.

Soft Tissue Sarcoma Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.4% over the forecast period (2024-2032)

Based on Treatment Type segmentation, Chemotherapy was predicted to show maximum market share in the year 2023

Based on End User segmentation, Hospitals were the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Soft Tissue Sarcoma Market- Segmentation Analysis:

The Global Soft Tissue Sarcoma Market is segmented based on Treatment Type, Route of Administration, Distribution Channel, End User, and Region.

The market is divided into five categories based on Treatment Type: Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, and Others. Chemotherapy currently dominates the treatment landscape in the soft tissue sarcoma market due to its longstanding efficacy and broad application across various sarcoma subtypes. Despite the emergence of targeted therapies and other advanced treatments, chemotherapy remains a cornerstone because of its ability to target rapidly dividing cancer cells systemically, making it suitable for both localized and metastatic disease. The versatility of chemotherapy regimens allows for their use in combination with other treatments such as surgery and radiation, thereby enhancing overall treatment effectiveness. Additionally, chemotherapy's established protocols and relatively lower costs compared to newer therapies contribute to its dominance in the market.

The market is divided into four categories based on End Users: Hospitals, Homecare, Speciality Centres, and Others. Hospitals serve as the primary end-users in the soft tissue sarcoma market, largely due to their comprehensive resources and capabilities in managing complex cancer treatments. Hospitals offer multidisciplinary care, which is crucial for sarcoma patients who often require a combination of surgery, chemotherapy, radiation, and supportive care. The presence of specialized oncologists, advanced diagnostic tools, and the ability to manage side effects and complications make hospitals the preferred setting for both initial and ongoing treatment. Furthermore, hospitals are often centers for clinical trials and advanced research, offering patients access to cutting-edge therapies and a higher standard of care.

Soft Tissue Sarcoma Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. The North American market is anticipated to register the largest market share during the forecast period, building on its leading revenue position in 2023. According to the American Cancer Society, an estimated 12,390 individuals were diagnosed with soft tissue sarcoma and associated cancers in 2016. Key factors driving market revenue growth include the high incidence rate of soft tissue sarcomas, increasing awareness of this condition, a growing focus on healthcare, and a well-established healthcare infrastructure.

Soft Tissue Sarcoma Market- Competitive Landscape:

In the competitive soft tissue sarcoma (STS) market, major players engage in strategic partnerships to enhance their offerings. By joining forces with other pharmaceutical firms, research institutions, or academic centers, companies can leverage their combined expertise, resources, and technologies to drive innovation and develop new treatments or diagnostic tools. These collaborations may also facilitate the sharing of data and knowledge, accelerating the pace of research and development. Additionally, partnerships can expand companies' market reach and enable them to access new geographic regions or patient populations. The demand for efficient therapies has grown alongside an increased incidence rate of tumors in general. Consequently, multinational corporations are investing a substantial portion of their earnings into research and development to create innovative pharmaceuticals. Several items connected to advanced medication delivery systems are awaiting FDA approval. It is anticipated that the rising demand for advanced drugs to treat gallbladder tumors will further drive market expansion.

Recent Developments:

In December 2020, the FDA granted an orphan drug designation to Moeculin Biotech's annamycin for soft tissue sarcoma.

In October 2020, Rafael Pharmaceuticals announced receiving an FDA grant of an Orphan Drug designation to CPI-613 (devimistat) indicated to treat soft tissue sarcoma. These designations underscore the importance of developing novel treatments for this challenging disease and highlight the ongoing efforts within the pharmaceutical industry to address unmet medical needs in soft tissue sarcoma.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL SOFT TISSUE SARCOMA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHT

Genentech USA

Pfizer, Inc.

Eli Lilly and Company

Bristol-Myers Squibb

Hoffmann-La Roche Ltd.

Johnson & Johnson, Inc.

GlaxoSmithKline

Teva Pharmaceuticals

Celgene Corporation

Others

GLOBAL SOFT TISSUE SARCOMA MARKET, BY TREATMENT TYPE - MARKET ANALYSIS, 2019 - 2032

Targeted Therapy
Chemotherapy
Anti-Angiogenesis Drugs
Radiation Therapy
Others

GLOBAL SOFT TISSUE SARCOMA MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Oral
Parenteral
Others

GLOBAL SOFT TISSUE SARCOMA MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy

GLOBAL SOFT TISSUE SARCOMA MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Homecare
Speciality Centres
Others

GLOBAL SOFT TISSUE SARCOMA MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Soft Tissue Sarcoma Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Soft Tissue Sarcoma Market Snippet by Treatment Type
- 2.1.2. Soft Tissue Sarcoma Market Snippet by Route of Administration
- 2.1.3. Soft Tissue Sarcoma Market Snippet by Distribution Channel
- 2.1.4. Soft Tissue Sarcoma Market Snippet by End User
- 2.1.5. Soft Tissue Sarcoma Market Snippet by Country
- 2.1.6. Soft Tissue Sarcoma Market Snippet by Region
2.2. Competitive Insights

3. Soft Tissue Sarcoma Key Market Trends

3.1. Soft Tissue Sarcoma Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Soft Tissue Sarcoma Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Soft Tissue Sarcoma Market Opportunities
3.4. Soft Tissue Sarcoma Market Future Trends

4. Soft Tissue Sarcoma Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Soft Tissue Sarcoma Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Soft Tissue Sarcoma Market Landscape

6.1. Soft Tissue Sarcoma Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Soft Tissue Sarcoma Market - By Treatment Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Treatment Type, 2023 & 2032 (%)
- 7.1.2. Targeted Therapy
- 7.1.3. Chemotherapy
- 7.1.4. Anti-Angiogenesis Drugs
- 7.1.5. Radiation Therapy
- 7.1.6. Others

8. Soft Tissue Sarcoma Market - By Route of Administration

8.1. Overview
- 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
- 8.1.2. Oral
- 8.1.3. Parenteral
- 8.1.4. Others

9. Soft Tissue Sarcoma Market - By Distribution Channel

9.1. Overview
- 9.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
- 9.1.2. Hospital Pharmacy
- 9.1.3. Online Pharmacy
- 9.1.4. Retail Pharmacy

10. Soft Tissue Sarcoma Market - By End User

10.1. Overview
- 10.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
- 10.1.2. Hospitals
- 10.1.3. Homecare
- 10.1.4. Speciality Centres
- 10.1.5. Others

11. Soft Tissue Sarcoma Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Soft Tissue Sarcoma Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Soft Tissue Sarcoma Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.9. Italy
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.9.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.9.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.3.9.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.10. United Kingdom
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. United Kingdom Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.10.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.10.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.3.10.6. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.11. France
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.11.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.11.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.3.11.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.12. Russia
  - 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.2. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.12.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.13. Netherlands
  - 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.2. Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.13.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.13.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.3.13.5. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.2. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.15. Poland
  - 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.2. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.15.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.16. Rest of Europe
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Soft Tissue Sarcoma Key Manufacturers in Asia Pacific
- 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. Asia Pacific Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 11.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.7. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.8. India
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.8.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.8.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.4.8.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.9. China
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.9.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.9.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.4.9.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.13. Thailand
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.14. Indonesia
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.5. Latin America
- 11.5.1. Overview
- 11.5.2. Soft Tissue Sarcoma Key Manufacturers in Latin America
- 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. Latin America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 11.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.7. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa
- 11.6.1. Overview
- 11.6.2. Soft Tissue Sarcoma Key Manufacturers in Middle East and Africa
- 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. Middle East and Africa Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 11.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.7. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Soft Tissue Sarcoma Industry

12.1. Competitive Dashboard
12.2. Company Profiles
- 12.2.1. Genentech USA
- 12.2.2. Pfizer, Inc.
- 12.2.3. Eli Lilly and Company
- 12.2.4. Bristol-Myers Squibb
- 12.2.5. Hoffmann-La Roche Ltd.
- 12.2.6. Johnson & Johnson, Inc.
- 12.2.7. GlaxoSmithKline
- 12.2.8. Teva Pharmaceuticals
- 12.2.9. Celgene Corporation
- 12.2.10. Others

13. 360 Degree Analyst View

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us